Inactive Instrument

Transition Therapeutics Inc Stock

Equities

Duration

Period

Style

Transition Therapeutics : Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.	16-08-25	PR
Transition Therapeutics : Receives Notification From NASDAQ	16-06-03	PR
Transition Therapeutics : Announces Third Quarter Fiscal 2016 Financial Results	16-05-11	PR
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST	16-05-09	PR
Transition Therapeutics : Provides Update on Type 2 Diabetes Drug Candidate TT401	16-04-18	PR

Managers	Title	Age	Since
Antonio F. Cruz CEO	Chief Executive Officer	71	98-07-05

Members of the board	Title	Age	Since
Antonio F. Cruz CEO	Chief Executive Officer	71	98-07-05

Sector

	1st Jan change	Capi.
CSL LIMITED	-5.99%	84.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.85B
BIOGEN INC.	-24.88%	27.69B
UCB	+53.61%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-8.08%	17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-33.74%	13.67B
INCYTE CORPORATION	-16.63%	11.86B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.19%	11.79B
SWEDISH ORPHAN BIOVITRUM AB	-2.25%	8.07B